For people living with treatment-resistant depression, finding something that actually helps can feel like an endless process of trial and error. Medications come and go, therapies are tried, symptoms persist, and years can pass without meaningful relief.
Now, a new clinical trial from King’s College London and South London and Maudsley NHS Foundation Trust has produced some striking results. Published in Nature Medicine, the study is the first publicly funded, placebo-controlled NHS trial of psilocybin-assisted therapy for treatment-resistant depression.
After receiving a single 25 mg dose of psilocybin alongside psychological support, 40% of participants were in remission three weeks after treatment. For a group who had already tried multiple conventional treatments, that’s a significant result.
Psilocybin and treatment-resistant depression
Treatment-resistant depression (TRD) generally refers to depression that has failed to respond adequately to at least two previous treatments. It affects around one-third of people with major depressive disorder, and for some, depression can persist for many years.
The participants in this trial had been living with significant depression for an average of around 20 years.
That makes the results particularly interesting. Psychedelic research has produced encouraging findings in recent years, but questions remain about how these treatments perform outside specialist research environments.
This trial was designed to explore exactly that: could psilocybin-assisted therapy work within the NHS (National Health Service)?
The answer, at least from this early study, looks promising.
What happened in the trial?
The researchers recruited 60 adults with treatment-resistant depression and randomly assigned them to receive either a single 25 mg dose of pharmaceutical psilocybin or a placebo.
Both groups received the same psychological support, including preparation before the dosing session, support during the experience and integration afterwards.
The difference between the groups became clear within just three weeks.
Among those who received psilocybin:
- 43% showed a clinical response
- 40% reached remission
- Improvements were also seen in anxiety, wellbeing, general health, and work and social functioning
In the placebo group, only 3% achieved either a clinical response or remission.
The benefits were still visible six weeks later. At that point, the response rate in the psilocybin group had increased to 50%, while the remission rate remained at 40%.
The researchers also reported that many of the effect sizes were exceptionally large for psychiatric research.
What does a psilocybin experience actually feel like?
Numbers tell one part of the story. The experience itself can be much harder to quantify. Speaking to The Independent, one participant described their psilocybin session as emotionally intense. During the experience, they recalled a vivid image of their father holding their sister, both of whom had died.
“It got very intense two or three times.”
They interpreted the experience as a sense of connection with their deceased family members:
“I felt like it was a way of them saying we are here.”
Afterwards, they described gaining a different relationship with their depression and emotions:
“It helped me understand my depression more and just feel my feelings.”
The experience was difficult at points, but the participant ultimately saw that difficulty as part of the process:
“It was very difficult — very painful — but I think that was what I needed.”
This kind of emotional processing is something researchers have repeatedly observed in psychedelic-assisted therapy. A psychedelic experience can bring difficult memories, grief and emotions into sharper focus, while the therapeutic setting gives people a place to work through what emerges.
Of course, the aim isn’t simply to have an interesting psychedelic experience. The psychological preparation and integration surrounding it are an important part of the treatment.
Is psilocybin therapy safe?
Safety is obviously a major consideration whenever psychedelic drugs are being investigated as medical treatments.
In this trial, most adverse events were mild, while serious adverse events were rare. Nearly two-thirds of recorded adverse events were judged to be unrelated to the study drug, and the researchers recorded no adverse events of special interest.
Overall, the treatment was considered generally well tolerated within the clinical setting used in the study.
Interestingly, the researchers also changed the location of the treatment partway through the trial. Rather than continuing exclusively in a hospital research facility, treatment was moved into a community mental health building.
No new safety concerns emerged. This could have important implications for the future of psychedelic therapy. If psilocybin-assisted treatment eventually becomes more widely available through healthcare systems, it may not require an intimidating hospital environment. A comfortable, carefully designed space with appropriately trained therapists could potentially be a better asetus for some patients.
The therapy matters too
One of the most interesting questions surrounding psychedelic-assisted therapy is how much of the benefit comes from the drug itself and how much comes from everything happening around it.
This study can’t completely separate those effects. Participants received psychological support before, during and after their psilocybin session, meaning the treatment was a combination of psychedelic medicine and therapy. And that may be, in part, the reason for this success story.
Psilocybin can produce an unusual state of consciousness in which thoughts, memories and emotions can be experienced from a different perspective. Within a supportive therapeutic environment, that temporary shift may give someone an opportunity to approach parts of their experience that have remained difficult to access.
For someone who has spent years caught in the same patterns of depression, creating space for a different perspective could be particularly meaningful.
There are still important caveats
As exciting as the findings are, this was a relatively small study, and participants were followed for only six weeks. Another important limitation was blinding. Almost everyone who received psilocybin correctly guessed that they had received the psychedelic, making it difficult to completely separate the pharmacological effects of psilocybin from expectations surrounding the experience.
The researchers themselves acknowledge these limitations. So, while the 40% remission figure is striking, it shouldn’t be interpreted as meaning that one dose of psilocybin will cure 40% of people with depression. Larger and longer trials will be needed to understand how durable the effects are, who is most likely to benefit, and how psilocybin-assisted therapy compares with existing treatments over the longer term.
Still, the findings represent an important step.
A glimpse of what psychedelic therapy could look like
Treatment-resistant depression remains one of the major challenges in mental healthcare. For people who have spent years trying conventional treatments without sufficient relief, the possibility of a completely different therapeutic approach is understandably significant.
This NHS trial suggests that psilocybin-assisted therapy can be delivered within a public healthcare setting while producing substantial improvements for some people with severe, treatment-resistant depression.
Professor James Rucker summed up the broader research landscape:
“The wider evidence base for psilocybin therapy is growing rapidly, and looks increasingly promising.”
